Streetbeat News

Price Targets

CBAY

Raymond James has maintained its Strong Buy rating for CymaBay Therapeutics (NASDAQ:CBAY) and increased its price target from $33.00 to $34.00. This new target represents a 106.56% increase from the current share price. CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver and other chronic diseases.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 5:00 pm

INGR

Stephens & Co. analyst Ben Bienvenu has reiterated an Overweight rating on Ingredion (NYSE:INGR) and maintained a price target of $130.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 4:55 pm

LPRO

Stephens & Co. analyst Vincent Caintic maintains an Equal-Weight rating on Open Lending (NASDAQ:LPRO) and lowers the price target from $9 to $6.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 4:53 pm

CNNE

Stephens & Co. analyst John Campbell has maintained an Overweight rating on Cannae Holdings (NYSE:CNNE) but lowered the price target from $36 to $30.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 4:43 pm

STKS

Stephens & Co. analyst Joshua Long maintains an Overweight rating on The One Group Hospitality (NASDAQ:STKS) but lowers the price target from $12 to $9.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 4:41 pm

HUBB

Seaport Global has initiated coverage on Hubbell (NYSE:HUBB) with a Buy rating and a price target of $325.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 4:35 pm

MQ

Susquehanna analyst James Friedman has initiated coverage on Marqeta (NASDAQ:MQ) with a positive rating and a price target of $9.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 4:31 pm

PSNL

Needham analyst Mike Matson has maintained a 'Buy' rating on Personalis (NASDAQ:PSNL) but lowered the price target from $7 to $2.3.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 4:26 pm

LCID

RF Lafferty analyst Jaime Perez has downgraded Lucid Gr (NASDAQ:LCID) from Buy to Hold and announced a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 4:24 pm

SEDG

GLJ Research analyst Gordon Johnson has maintained a 'Sell' rating on SolarEdge Technologies (NASDAQ:SEDG) and lowered the price target from $35.55 to $34.42.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 4:24 pm